Stryker in the news

Stryker has appointed Spencer Stiles as its next CEO, with current CEO Kevin Lobo transitioning to Executive Chair of the Board of Directors.

Stryker announced Kevin Lobo will transition from CEO to Executive Chair, with Spencer Stiles, the current President and COO, becoming CEO effective January 1, 2027.

Stryker announced that Spencer Stiles will succeed Kevin Lobo as CEO on January 1, with Lobo transitioning to executive chair of the Board of Directors as part of a planned succession.

Stryker announced that Spencer Stiles will take over as CEO from Kevin Lobo on January 1, 2027, with Lobo becoming executive chair.

Stryker announced its planned leadership succession, with Kevin Lobo transitioning to Executive Chair and Spencer Stiles becoming CEO, effective January 1, 2027.

Stryker's stock increased by 3.32% driven by investor bargain hunting and positive analyst sentiment, despite ongoing supply chain and manufacturing challenges.

Stryker launched Mako 4 SmartRobotics, the fourth generation of its robotic-arm assisted technology for joint replacement, in India.

Stryker stock, trading at $275.60 on Pluang with a 0.06% daily increase, has a market cap of $116.27 billion and a 1.28% dividend yield, following an upgrade to 'Strong Buy'.

Stryker (SYK) has been upgraded to 'Strong Buy' following a price pullback to $275, showing strong organic sales growth, driven by Mako robots, ASC expansion, and Smart Care platform, and is expected to deliver double-digit EPS growth.

Stryker's stock is undervalued by 32.1% at $285.22 according to GF Value™, despite strong profitability, but insider selling raises caution.

Stryker's stock rating was downgraded to "hold" by Wall Street Zen, despite reporting strong quarterly earnings and increased institutional investment, alongside significant insider stock sales.

Stryker's stock faces mixed analyst ratings and varied price targets ahead of its third-quarter results, despite strong second-quarter financial performance.

Stryker is being investigated by a securities firm, with its stock trading near its 52-week low but showing a slight daily gain and a 1.28% dividend yield.

Stryker will host a webcast on October 29, 2026, to discuss its third quarter 2026 financial results, with a press release issued concurrently.

Stryker's shares plunged after its CFO disclosed that a manufacturing problem in the Peripheral Vascular unit is continuing, leading to a significant market value drop and an investigation.

Stryker will announce its third-quarter 2026 financial results via webcast on October 29, 2026.

Stryker is facing a shareholder investigation due to a persistent manufacturing issue in its Peripheral Vascular unit, acquired through Inari Medical, which has led to significant stock price drops and questions about the company's transparency.

Stifel cut its price target on medical technology company Stryker to $330 from $360 due to anticipated revenue pressures and a challenging outlook for 2026.

A comparison of Stryker and ResMed, two medical device companies, highlights Stryker's growth through acquisitions and operational challenges against ResMed's stronger profitability and market share gains.

Stryker's CFO, Preston Wendell Wells, transferred 109 shares from an employee stock plan due to a matrimonial settlement, reducing his direct holdings to 3,661 shares.